Elanco Animal Health Incorporated (NYSE:ELAN) Receives $16.75 Consensus Target Price from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) have received a consensus recommendation of "Hold" from the nine analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $16.75.

Several brokerages have issued reports on ELAN. Morgan Stanley downgraded shares of Elanco Animal Health from an "overweight" rating to an "equal weight" rating and cut their price objective for the stock from $17.00 to $15.00 in a research report on Thursday, September 19th. Barclays lifted their price target on Elanco Animal Health from $19.00 to $20.00 and gave the stock an "overweight" rating in a report on Friday, November 8th. UBS Group started coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a "buy" rating and a $18.00 price objective on the stock. Stifel Nicolaus reissued a "buy" rating and issued a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a "market perform" rating and a $14.00 price objective for the company.

Elanco Animal Health Stock Up 0.2 %

Shares of NYSE ELAN traded up $0.03 during trading hours on Monday, hitting $12.13. The company had a trading volume of 3,459,503 shares, compared to its average volume of 4,770,483. Elanco Animal Health has a 1-year low of $11.40 and a 1-year high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The firm's 50 day moving average is $13.22 and its 200-day moving average is $14.30. The stock has a market capitalization of $6.00 billion, a P/E ratio of 30.38, a price-to-earnings-growth ratio of 2.03 and a beta of 1.41.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.12 by $0.01. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the business earned $0.18 earnings per share. The business's revenue was down 3.6% compared to the same quarter last year. On average, analysts expect that Elanco Animal Health will post 0.92 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Elanco Animal Health

Large investors have recently modified their holdings of the stock. Commerce Bank grew its holdings in shares of Elanco Animal Health by 2.2% in the third quarter. Commerce Bank now owns 35,114 shares of the company's stock worth $516,000 after acquiring an additional 741 shares during the period. HBK Sorce Advisory LLC lifted its position in shares of Elanco Animal Health by 9.4% in the 2nd quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company's stock worth $186,000 after purchasing an additional 1,107 shares during the period. Atomi Financial Group Inc. increased its position in shares of Elanco Animal Health by 11.1% during the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company's stock worth $177,000 after purchasing an additional 1,221 shares in the last quarter. Keene & Associates Inc. raised its holdings in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company's stock worth $337,000 after buying an additional 1,240 shares during the last quarter. Finally, Resonant Capital Advisors LLC lifted its holdings in Elanco Animal Health by 5.0% in the second quarter. Resonant Capital Advisors LLC now owns 27,325 shares of the company's stock valued at $394,000 after acquiring an additional 1,306 shares during the period. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.